BACHEM

COMPANY BROCHURE

CONTENTS

WHAT YOU CAN EXPECT FROM US

As the world's leading expert in the development and production of peptides and oligonucleotides (TIDES), Bachem is a strategic partner in Biotechnology, Pharmaceuticals, Diagnostics, Cosmetics and Life Science research.

To ensure the supply of these complex molecules, Bachem brings together a unique mix of experienced people, innovation, long-term customer relationships, commitment to excellence and quality in a sustainable approach to business. These principles are reflected in our strategic foundations. Together, these strengths create a distinctive value proposition that helps Bachem's customers achieve their goals more effectively.

Ultimately, our commitment is in enabling innovative treatments to reach patients worldwide, safely and at scale.

STRATEGIC FOUNDATIONS

PEOPLE AND CULTURE

Highly skilled employees

CUSTOMER CENTRICITY & SERVICE

Trusting Partnership

INNOVATION & TECHNOLOGY

Developing new Ideas together

OPERSTIONAL EXCELLENCE & QUALITY

Top performance & high standards

SUSTAINABILITY

Long-term perspective

AN ENTREPRENEURIAL SUCCESS STORY

1971

Founded by entrepreneur Peter Grogg as Bachem Feinchemikalien AG

1978

First contract manufacturer to produce peptides to GMP quality standards, first API produced: Thymopentin



1989

Breakthrough with the commercial production of the decapeptide goserelin, a synthetic analogue of the naturally occurring gonadotrophin-releasing hormone (GnRH)



1996

Acquisition of the second largest manufacturer of peptides, Bachem California in Torrance, USA, together with its subsidiaries in Germany and the UK

1998

Going public: Bachem shares were now listed on the Swiss Stock

1999

Acquisition of Peninsula Laboratories, Inc., based in San Carlos, California, and its subsidiary in England, which is merged with Bachem UK – itself originally a subsidiary of California-based Bachem Inc. in 2000

2001

Acquisition of Sochinaz SA, a Swiss-based (Vionnaz) specialized manufacturer of active pharmaceutical ingredients

2015

Acquisition of the American Peptide Company (APC), also specialized in the production of peptides and based in Vista, California

2018

Establishing Bachem Japan K.K. in Tokyo to enhance project and customer support with local presence in Asia

2018

Strategic decision to significantly expand the product range and to position Bachem in the future as a supplier in the development and production of oligonucleotides

2020

Despite the COVID-19 pandemic, we were able to secure the systemically important supply of active ingredients. We even increased in critical areas and did high investments at all sites



2021

What started out as a small laboratory has grown into a company that employs over 1,500 people at six locations worldwide

50 YEARS BACHEM

2025

Building K: The largest expansion project in Bubendorf is expected to go into production, facilitating the growing demand for large-scale manufacturing of TIDES

People and Culture

Customers benefit from working with one of the world's most experienced teams in TIDES, whose deep expertise drives innovation and ensures consistent delivery. The development and retention of highly skilled industrial and scientific talent directly support customer success across all stages of drug development.

Innovation and Technology

Partners gain access to cutting-edge technologies that continuously push the boundaries of TIDES manufacturing. Ongoing advancements in process efficiency and environmental sustainability such as solvent reduction help improve cost-effectiveness and reduce ecological impact.

Sustainability

Customers and stakeholders are supported by a long-term commitment to responsible business practices. From healthcare contributions to environmental stewardship and employee wellbeing, sustainability is embedded across all operations to ensure lasting value.

Customer Centricity and Service

Strategic customer relationships are built on trust, collaboration, and shared goals. Customers receive proactive support to overcome supply challenges and accelerate the clinical development of life-saving medicines.

Operational Excellence and Quality

A strong reputation for quality and a focus on operational efficiency help ensure high yields and reliable performance in TIDES manufacturing–delivering consistent results that customers can depend on.

PRODUCTS AND SERVICES

Customers benefit from tailored solutions that address the demands of scaled-up TIDES production, alongside the specialized expertise required for process development and manufacturing materials during clinical development. These diverse needs are met through three distinct operating modes, each designed to align with specific stages of development and production:

CMO: Contract Manufacturing Organization

Efficient, high-quality manufacturing of approved medicines ensures a dependable supply for millions of patients worldwide, especially those living with chronic diseases. By maintaining consistent production and addressing peptide drug substance shortages, customers benefit from stable market presence and predictable cash flow, helping them meet both clinical and commercial demands with confidence.

CDMO: Contract Development and Manufacturing Organization

Customers advancing clinical-stage therapies benefit from specialized support and reliable production of drug materials, accelerating development timelines and increasing the potential for regulatory approval. Access to deep TIDES expertise, continuously sharpened through a strong pipeline of development projects, lays the foundation for future commercial manufacturing and contributes to the delivery of therapies that address critical unmet medical needs.

"Trailblazing" CDMO: Going beyond today's technology standard

"Trailblazing" at Bachem involves developing new technologies - independently or with partners - to improve how TIDES are made. These efforts help solve manufacturing challenges, enhance sustainability, and ensure we stay relevant to our customers over the long term.



CMO

Contract Manufacturing Organization

- Efficient high-quality manufacturing for approved drugs
- Contributes to supply of approved medicines for patients worldwide

CDMO

Contract Development and Manufacturing Organization

- Expert services and production for drug material during clinical development
- Supports rapid approval for novel medicines that patients are waiting for

«Trailblazing» CDMO

Going beyond today's technology standard

- New technologies that address manufacturing challenges
- Open new ways in which TIDES can be made as ingredients for medicines

At Bachem, we are dedicated to offering a comprehensive portfolio of products and services that provides support to pharmaceutical and biotechnology companies worldwide.

Research and Specialties

Academic institutions, diagnostic developers, and specialty innovators gain access to high-quality catalog products and custom synthesis, including peptides, amino acid derivatives, and tailored solutions for unique scientific challenges.

CMC Development

Biotech and pharma companies advancing clinical-stage therapies rely on expert support in process development, scale-up, and regulatory guidance for peptides and oligonucleotides, ensuring a smoother path to market readiness.

Commercial API Manufacturing

Global pharmaceutical companies benefit from large-scale GMP production of approved drug substances, securing consistent supply and supporting treatment access for millions of patients worldwide.

Research & Specialties

Peptides and chemical compounds for research, early discovery, cosmetics and diagnostics

CMC Development

Supply of APIs and compounds for clinical research with peptides and oligonucleotides and related services

Commercial API

Manufacturing and supply of peptide and oligonucleotide APIs for approved drugs (patent-protected and generics)

We provide products for research, clinical development and commercial application to support customers from academia, pharmaceutical and biotechnology companies worldwide.

RESEARCH AND SPECIALTIES

Automated microwave-assisted peptide synthesizers are a key of Bachem UK's toolbox. Microwave technology enables a significant reduction in both amino acid coupling cycle times and solvent consumption compared to conventional synthesis.

Bachem supports researchers worldwide with a broad portfolio of amino acid derivatives and peptides, available through both catalog and custom synthesis. Our catalog products – mainly manufactured in St. Helens, UK and Bubendorf, Switzerland – are offered in various pack sizes and shipped globally from our distribution centers. These are used in academic, biological, and medical research, and are intended for laboratory use only. They can be purchased via the Product Catalog on our website **shop.bachem.com/.**

Custom Synthesis Tailored to Your Needs

Customers working across research, development, and production benefit from flexible custom synthesis services–covering everything from simple peptides to highly complex molecules, produced to exact specifications. Whether small-scale or large-volume, GMP or non-GMP, each project is supported with tailored analytics, vialing, and sequence design. For time-sensitive projects, the Express Manufacturing service ensures rapid turnaround to keep development on track.

Specialized Peptides for Cosmetics and Diagnostics

Innovators in cosmetics and in vitro diagnostics (IVD) gain access to sustainable peptide manufacturing powered by Molecular Hiving™–an environmentally friendly approach free from CMR substances. Manufacturing is adapted to meet varying scales and specifications, with documentation support through Bachem Quality Grade (BQG). For medical device developers, our ISO 13485-certified UK site provides high-quality peptides as critical raw materials, backed by dedicated equipment and robust quality systems. From early development to market launch, customers are supported every step of the way.

> We have developed a great partnership with Bachem AG since 2017. Real-time professional communication with Bachem specialists provided us with critical support for our products and allowed us to develop novel diagnostics solutions. High level of service and customer centricity are just a few of the great qualities we experienced with Bachem team. R-Biopharm is looking forward to strengthening this collaboration and, without any doubt, recommends Bachem as a reliable and trustable partner! "

Yanis Tolstov
Chief Medical Officer

r-biopharm

ENQUIRY	PROCESS DEVELOPMENT	SPECIFICATIONS	COMMERCIAL SUPPLY
• Sequence supplied by customer • Identification of customer needs	• 2 to 3 Independent Research Grade batches • Definition of additional services	• Customer specification dossier • Bachem technical specification sheet • Master production record • Quality agreement	• Batch production record available for review on-site • Critical change control • Supply based upon purchase order or supply agreement
Evaluation completed	**Process established**	**Specifications defined**	**"Research Grade Plus" peptides provided**

A large selection of modifications (N-, C-terminal and backbone) on offer:

- Acetylation, formylation, acylation
- Amidation
- Biotinylation
- Branched peptides
- Chromogenic and fluorogenic carboxypeptidase substrates
- Clickable peptides
- Conjugation to polymers, proteins and small molecules (including imaging agents)
- Cyclizations, head to tail and side chain (lactam bridge, thioether)
- Dye labeled peptides
- Hydrocarbon-stapled peptides
- Incorporation of fluorophores or chromophores
- Incorporation of D-enantiomers and unusual amino acids
- Introduction of C-terminal alcohol and aldehyde moieties
- Introduction of C-terminal ester and thioester groups
- Labeling with stable isotopes
- Labeling with Tide FluorTM and Tide QuencherTM
- Ligations
- Lipidation
- Maleimido peptides
- Methylation, alkylation
- Multiple disulfide bond formation
- Phosphorylation and sulfation
- Retro-inverso peptides
- Stabilizing modifications including PEGylation, N-methylated amino acids and reduced peptide bonds

CHEMISTRY, MANUFACTURING AND CONTROL OF NEW CHEMICAL ENTITIES

Bachem offers integrated services to its customers to support support peptide and oligonucleotide drug development–from early research through to commercial supply. Bachem's integrated CMC approach helps streamline clinical and regulatory progress, reducing risk and accelerating timelines. Customers gain access to both research-grade and GMP-grade peptides, including complex peptides and synthetic proteins, with comprehensive analytical support across all development phases to ensure quality, compliance, and readiness for market.

Expanding our expertise to oligonucleotides, we apply our longstanding chemical expertise to deliver high-quality APIs. With decades of experience and strong regulatory engagement, we build long-term partnerships with our customers that help bring life-changing therapies to market. Our work is guided by a strong commitment to advancing global healthcare and improving patients' lives.



Bachem offers expertise in 170 peptides, oligonucleotides, small molecule or peptide conjugated New Chemical Entities (NCE) projects that are in different phases of preclinical or clinical development.

Our services in the process of drug development

DISCOVERY	DEVELOPMENT				LAUNCH & MARKETED PRODUCT
RESEARCH	PRECLINICAL	CLINICAL I	CLINICAL II	CLINICAL III	MARKET SUPPLY
	API MANUFACTURING				
	non-GMP batch	GMP batches			Large Scale Manufacturing
	PROCESS DEVELOPMENT				
	Process development	Scale up	Process validation		
	ANALYTICS				
	Method development	Method validation			
	STABILITY				
	Developmental stability studies	ICH stability studies			Follow up stability studies (FUST)
	REGULATORY DOCUMENTS				
	CMC Doc. phase I	CMC Doc. phase II	CMC Doc. phase III		Common Techical Document (CTD) Module 3
From Investigational New Drug (IND) & Investigational Medicinal Product Dossier (IMPD) →					To New Drug Application (NDA) & Marketing Authorization Application (MAA)

DURING PRECLINICAL	
CHEMICAL DEVELOPMENT & API SYNTHESIS	**Feasibility study/manufacturing of non-GMP material** • Process development (synthesis and purification) • Obtained material can be used for toxicology studies, stress testing, formulation studies and initial analytical method development • Technology transfer from non-GMP to GMP **GMP manufacturing** • Starts at the end of the preclinical phase • GMP material is mandatory for phase I clinical trials
ANALYTICAL DEVELOPMENT STABILITY/ANALYTICS	**HPLC method development** **Stress testing** (strongly recommended) • Forced degradation, influence of temperature and moisture in the solid state • Hygroscopicity, photostability • Essential to get information for determining handling, shipment and storage conditions • Prerequisite for the analytical method development of the High-Performance Liquid Chromatography (HPLC) purity method
REGULATORY DOCUMENTS	**Preparation of CMC documentation to enter phase I** • Provided to customer for inclusion into their regulatory submissions

DURING CLINICAL PHASE I	
MANUFACTURING	**GMP manufacture** • Process development • Scale-up
STABILITY	**Developmental stability studies** (recommended) • Custom protocols available • Stability under different storage conditions at defined periods of time
ANALYTICS	**Validation of analytical methods** • Purity and assay **Characterization of reference standard** • Portioning of solid reference material into vials (individually labeled and sealed) • Release by Quality Assurance (QA) with Certificate of Analysis • Storage under controlled conditions, regularly tested
REGULATORY DOCUMENTS	**Preparation of CMC documentation to enter phase II** • Provided to customer for inclusion into their regulatory submissions

DURING CLINICAL PHASE II & III	
MANUFACTURING	**GMP manufacture** • Scale-up **Master Batch Production Record (MBPR)** • Manufacturing of confirmation batch according to MBPR **Process validation** • Manufacturing of 3 validation batches (demonstrate reproducibility and consistency of process) • Batch size should represent batch size of post-market approval
STABILITY	**ICH stability studies** • Meeting regulatory requirements for commercial applications
ANALYTICS	**Validation of analytical methods** • Validation according to ICH guideline Q2 • E.g., peptide content, purity, water content, acetate content, residual solvents, bioburden • Must be completed prior to release testing of the validation batches
REGULATORY DOCUMENTS	**Preparation of CMC documentation for phase III** • Provided to customer for inclusion in their regulatory submissions **Preparation of review of Module 3** • Provided to customer for inclusion in their regulatory submissions

COMMERCIAL ACTIVE PHARMACEUTICAL INGREDIENTS

Using the innovative Multicolumn Countercurrent Solvent Gradient Purification (MCSGP) technology, we ensure a more sustainable and streamlined large-scale purification of APIs.

Scalable API Manufacturing for Global Impact

Pharmaceutical companies benefit from large-scale manufacturing of peptide and oligonucleotide APIs, supported by strong synergies across both platforms. Products are manufactured at cGMP facilities in Europe and the US, inspected by the FDA and national authorities, with volumes reaching hundreds of kilograms or tons annually. Tailored technical and regulatory support–including over 80 submitted Drug Master Files (DMFs) worldwide–helps streamline INDs, NDAs, and ANDAs.

Approved drugs for a wide range of diseases rely on commercial peptide and oligonucleotide NCEs produced at scale. Nearly one-third of all commercial peptide APIs and several oligonucleotide APIs available today are manufactured by Bachem. Capabilities aligned with FDA's ANDA guidelines enable the supply of synthetic peptides as generics, which we constantly strive to update to ensure an attractive long-term supply. Long-term supply agreements reflect the trust placed in Bachem's reliability and quality. To explore available products or pipeline opportunities, **visit our website.**



Customers from all over the world source generic APIs from Bachem.

It is an absolute delight to work and collaborate with Bachem. Bachem has a unique ability to develop, manufacture, and supply high-quality products that enable us to develop and commercialize clinically critical therapies. In addition, their entire global and cross functional team – from technical, regulatory, business development, to customer service – are dedicated to ensuring that we are well taken care of! It is safe to say that Bachem sets a high bar for quality and customer delight."

Nailesh A. Bhatt,
CEO

VGYAAN PHARMACEUTICALS

GENERIC PEPTIDE APIS

Generic API	CEP/DMF	Application	Site
Atosiban	DMF	Reproductive Medicine	CH
Buserelin	DMF	Oncology, Reproductive Medicine	CH
Glucagon	DMF	Diabetes Mellitus	CH
Gonadorelin Acetate	CEP, DMF	Oncology, Reproductive Medicine	CH
Goserelin Acetate	CEP, DMF	Oncology, Reproductive Medicine	CH
Lanreotide	DMF	Oncology	USA
Leuprolide Acetate	CEP, DMF	Oncology	CH
Octreotide Acetate	CEP, DMF	Oncology	CH
Somatostatin	CEP	Gastritis	CH
Teriparatide Acetate / pTH (1-34) (human)	DMF	Osteoporosis	USA
Tetracosactide	CEP, DMF	Oncology, Diagnostics	CH
Triptorelin Acetate	CEP, DMF	Oncology, Reproductive Medicine	CH
Triptorelin Pamoate	CEP	Oncology, Reproductive Medicine	CH
Liraglutide	DMF	Diabetes Mellitus	USA

SMALL MOLECULE APIS

Generic API	CEP/DMF	Application	Site
Carbidopa	CEP, DMF	Epilepsy and Parkinson's Disease	CH
Etomidate	CEP, DMF	Sedatives and Anesthetics	CH
Propofol	CEP, DMF	Sedatives and Anesthetics	CH

If you do not find your API of interest in this list, please reach out to us.

Please note: Some products may be restricted in certain countries.

INNOVATING FOR BETTER MANUFACTURING

Bachem has always attached great importance to innovation in manufacturing for the chemical synthesis of TIDES. This enables customers to achieve cost and efficiency advantages and at the same time unlocks more environmentally friendly manufacturing processes. Bachem is one of very few manufacturers that can take highly specialized expertise from the production of complex peptide molecules and apply it to the further development of oligonucleotide production technology. Innovation management at Bachem is based on three pillars: improvements in production technology, in business processes, and broad, continuous improvements in all business areas.

Innovation drivers: Complexity, large quantities and environmental

The growing molecular complexity of new peptide drugs often necessitates chemical synthesis. As these drugs are increasingly used in large patient groups and oral formulations rise, manufacturing capacity is rapidly expanding. This growth offers opportunities for contract manufacturers but also brings economic and ecological challenges. Chemical API production requires significant raw materials and solvents. Today, pharmaceutical companies demand more efficient, sustainable processes that reduce environmental impact while maintaining high quality and offering optimal material choices.

Green Chemistry - Improved manufacturing processes as a contribution to environmental protection

We aim to redesign our processes to minimize the use and generation of hazardous substances and their environmental impact. That's why we have implemented new solutions for greener peptide synthesis by replacing potential harmful solvents whenever possible. Jitsubo's Molecular Hiving™ technology is one example of how we are already achieving this. It is a liquid phase peptide synthesis using a hydrophobic tag onto which the peptide is assembled in the same way as onto the resin in Solid Phase Peptide Synthesis (SPPS). Solvents and reagents classified as carcinogenic, mutagenic or toxic for reproduction can be entirely avoided. Many washing and filtration steps are not necessary with this technology, resulting in a reduction of organic solvents in the production of peptides by up to 60%. Bachem is also conducting research into new processes in which the use of perfluorinated and polyfluorinated alkyl compounds, known as PFAS or "forever chemicals", can be reduced in the production of active ingredients.

More efficient purification

Purification is not only paramount for achieving a high purity but also a major determinant for the productivity of the whole manufacturing process of APIs. The innovative Multicolumn Countercurrent Solvent Gradient Purification (MCSGP) technology represents great progress in the downstream process for peptide and oligonucleotide manufacturing; compared to single-column batch purification, solvent consumption is typically decreased over 30%, thus contributing to a higher level of sustainability. Whereas with batch processes achieving the target purity often goes with a decrease of yield and productivity, MCSGP provides high yields of product without negative impact on purity. The automated system runs 24/7 and has potential for additional reductions in cycle time of up to 70%. Bachem is the first company to use this technology, developed by a start-up from ETH Zurich, in the area of TIDES and has, for example, equipped the new production building K with corresponding systems for large production volumes.

Isolation with patented lyophilization trays

Lyophilization of bulk material is a common step in improving the stability and handling of APIs and related innovations mean key improvements for API manufacturing. We have developed our own closed lyophilization tray made from stainless steel, a material well established in API production and not prone to issues with leachables. Our technology allows for the lyophilization of high volumes of GMP material, while the loading and unloading are easy and convenient. These patented lyophilization trays allow for a constant monitoring of temperature during the lyophilization of products. With these unique closed lyophilization trays, we can handle highly active peptides and oligonucleotides down to Occupational Exposure Band (OEB) levels of 100 ng / m^3 safely.

With our patented closed lyophilization trays developed in-house, we handle high volumes safely with a strict containment protocol.

EXPERTISE AND EQUIPMENT AT OUR SITES

We manufacture APIs with excellent batch-to-batch reproducibility. This guarantees consistent high quality and makes us a reliable partner for you. Our facilities are located in Switzerland, the UK, Japan and the USA. All cGMP sites are inspected by the FDA and national authorities, such as the Swissmedic.

Bubendorf (CH) Vionnaz (CH)	Founded in 1971 Acquired in 2001
Torrance (CA) Vista (CA)	Acquired in 1996 Acquired in 2015
Tokyo (JP)	Established in 2018
St. Helens (UK)	Acquired in 1999
GMP Sites	

Large-scale production of peptides and oligonucleotides

Bachem AG, Switzerland, Bubendorf

Our headquarters in Bubendorf hosts Bachem's largest GMP production facility for peptides and oligonucleotides, with batch capacities exceeding 15 kg. It serves as a central hub for research, specialty products, and services across Europe, Africa, India, and the Middle East, and is licensed for API manufacturing for the Japanese market. The site integrates cGMP process development, manufacturing, project management, regulatory support, and supply chain operations.

Peptide production uses SPPS, Liquid Phase Peptide Synthesis (LPPS), and Molecular Hiving™ technology, while oligonucleotide manufacturing includes Solid Phase Oligonucleotide Synthesis (SPOS), Stirred-Bed SPOS (SB SPOS), Tag-assisted One-Pot Liquid Phase Oligonucleotide Synthesis (TOP LPOS), and enzymatic ligation. Advanced analytical capabilities include among others HPLC, Ultra High-Performance Liquid Chromatography (UPLC), high-resolution mass spectrometry (MS), electrospray ionization MS (ESI MS) and matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS).

To better serve customers in peptide and oligonucleotide development, one of the world's most advanced production facilities is set to begin operations in 2025–enhancing capacity and accelerating delivery timelines. In addition, a new site in the Swiss industrial area of Sisslerfeld is being planned to support large-scale manufacturing, ensuring reliable supply for growing global demand.

Medium-range production of API

Bachem Americas Inc., VistaCalifornia, US

This site is a medium-to-large-volume cGMP manufacturing facility for commercial API, peptide NCEs and intermediates. The necessary infrastructure has been installed to support a full array of large-scale manufacturing capabilities for SPPS. Here we produce APIs like liraglutide. This site is licensed for the manufacture of APIs for the Japanese market.

Small-range production of APIs

Our cGMP site in Torrance, U.S. is a center of excellence for peptide NCE development using SPPS. It combines deep CMC expertise with efficient small-to-medium-scale manufacturing, producing tens of kilograms annually. Peptides like vasopressin, desmopressin, exenatide, and vasoactive intestinal peptide (VIP) are made here.

The site also leads in peptide API characterization, offering advanced analytics including among others HPLC, UPLC, high-resolution MS, and multi angle light scattering (MALS). It is licensed for API manufacturing for the Japanese market.

Bachem Americas Inc., Torrance, California, US

Center of competence for small molecules

At this site customers benefit from high-capacity GMP manufacturing of small organic molecules, short peptides, and amino acid derivatives–supporting production needs across multiple facilities. With expertise in advanced chemical processes such as chiral synthesis, metal catalysis, enzymatic reactions, and continuous flow technology, the site enables an annual API output exceeding 200 tons.

As the global leader in propofol production, customers gain access to a sustainable, solvent-free manufacturing process powered by highly automated equipment–recognized by the product's inventor as a superior approach. The site is also licensed for API production for the Japanese market, ensuring compliance with international regulatory standards and supporting global distribution strategies.

Bachem SA, Vionnaz, Switzerland

Preferred partner for diagnostics companies

At our ISO13485-certified UK center of excellence for research chemicals, we produce over 1,500 peptides annually via SPPS, ranging from milligram to gram scale. Since 2017, the site has specialized in peptides for use in medical devices and IVDs, offering a full suite of related services. To meet growing demand for customized peptide aliquots, especially for IVD sets, we've implemented an automated powder dispensing system. This upgrade enhances speed, ensures weighing accuracy, maintains full traceability, and eliminates transcription errors - ultimately reducing delivery times without compromising quality.

Bachem UK Ltd., St. Helens, England, Europe

Service for our customers in the Asia pacific region

Our Tokyo office serves as a key hub for supporting partners across Asia Pacific. With a dedicated local team, we engage directly with the market, focusing on APIs - including generics, peptides, and oligonucleotide NCEs. Being close to our customers in language, culture, and location is essential to delivering excellent service.

Bachem Japan K.K., Tokyo, Asia

OUR COMMITMENT TO SUSTAINABILITY

At Bachem, we are committed to sustainability by taking responsibility for our employees, the society, and the environment. We take responsibility for future generations through careful handling of resources and avoiding environmental risks. This commitment is reflected in our corporate social responsibility (CSR) strategy, which is aligned with United Nations sustainable development goals. Our CSR goals and measures are updated on an annual basis. Thus, we have excellent environmental figures with a comparatively low environmental impact, as well as a level of resource consumption relative to economic output. After participation in the Responsible Care® program for more than 20 years, we introduced a new program for CSR in 2020 and received an EcoVadis Platinum Rating in 2022, followed by a Gold Medal at the end of 2023. This placed us among the top 2% of all companies rated and in the top 1% within the Basic Pharmaceuticals and Pharmaceutical Preparations industry. In May 2025, we again received the EcoVadis Gold Medal, with a further improved score, reflecting a position within the top 5% of companies evaluated globally. The rating recognizes Bachem's performance in areas such as the environment, sustainable procurement, ethics as well as labor and human rights. Bachem reports with the Carbon Disclosure Project and, as a member of the United Nations Global Compact, on their corresponding Communication on Progress (CoP).

With our commitment to sustainability, we demonstrate that we are not only a leader in the production of peptides and oligonucleotides for research, clinical development, and commercial application, but also in delivering on our broader promise to meet the highest standards possible in corporate social responsibility for a better world tomorrow.

GOLD | Top 5%
ecovadis
Sustainability Rating
MAY 2025

FOR MORE INFORMATION: BACHEM KNOWLEDGE CENTER

We offer a wide range of documentation, calculators and practical information on our various products and services in the knowledge center on our website (https://www.bachem.com/knowledge-center/).

I truly feel comfortable selecting Bachem as API partner for our complex formulation need. Bachem always comes with innovative research which make them stand tall in this highly competitive environment. Working with Bachem, I don't recollect any points which were not resolved, and when we have to go open ended for our ANDA submission, their customer service support is indeed superb. I can say that Bachem knows science, Bachem knows regulatory requirements, Bachem knows service which gives ultimate peace of mind to us, and we are always confident that we tied knot with perfect API partner."

Kushal Shah,
Manager
amneal

BACHEM

GLOBAL BUSINESS

Bachem facilities are located in Switzerland, the UK, the US and Asia. All cGMP manufacturing sites are inspected by the US-FDA and national authorities.

About Bachem:

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.

myclimate neutral

FSC www.fsc.org RECYCLED Papier aus Recyclingmaterial FSC® C017887

Marketing & Sales Contact

Americas

Bachem Americas, Inc.
Tel. +1 888 422 2436
(toll free in USA & Canada)
+1 310 539 4171
sales.us@bachem.com

Asia Pacific

Bachem Japan K.K.
Tel. +81 3 6661 0774
sales.jp@bachem.com

EMEA and India

Bachem AG
Tel. +41 58 595 2020
sales.ch@bachem.com

Visit our website www.bachem.com
or shop online shop.bachem.com

www.bachem.com

2007324 published by Global Marketing, Bachem AG, October 2025